74.30
+3.4(+4.80%)
Currency In EUR
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
69
First IPO Date
September 30, 2016
| Name | Title | Pay | Year Born |
| Mr. Marc M. P. de Garidel M.B.A. | Chief Executive Officer & Director | 630,942 | 1958 |
| Mr. Jerome Denis Ph.D. | Executive Vice President of Process Development & Manufacturing | 0 | N/A |
| Mr. Patrick Malloy | Senior Vice President of Investor Relations | 0 | N/A |
| Ms. Ida Hatoum | Chief People & Compliance Officer | 0 | 1975 |
| Mr. Didier Scherrer Ph.D. | Chief Scientific Officer | 0 | 1970 |
| Mr. Didier Blondel | EVice President, Chief Financial Officer & Board Secretary | 0 | 1964 |
| Mr. Pierre Courteille M.B.A. | Chief Business Officer | 0 | 1969 |
| Hema Keshava | Senior Vice President of Finance | 0 | N/A |
| Chris Rabbat Ph.D. | Vice President & Global Head of Medical Affairs | 0 | N/A |
| Kevin Shan Ph.D. | Vice President & Global Head of Biometrics | 0 | N/A |
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.